Breast Cancer | Pharmacor | G7 | 2014

Last Updated 16 September 2014
Owing to its large population, the treatment of breast cancer remains an active area of research with a rich and diverse product pipeline. A competitive current therapies market means that barriers to entry are high, and relatively few of the many therapies in development will enter this lucrative market. Treatment is currently determined based on hormone-receptor and HER2 expression, and successful therapies are often those tailored to specific subpopulations.

Login to access report